Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase II randomized placebo-controlled trial.

Dev Med Child Neurol · 2025 · PMC11875526 · PMID 39340758

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Visual sustained attention showed a trend towards better performance in the lamotrigine group (−0.81, 95% CI −1.67 to 0.04).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.